Physician profile
Thomas Moore
NPI 1700410081
$1,219.25
in general payments reported to CMS, 2019-2025
20 companies · $269 in 2025
The $269 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $98.37 · 2022: $76.81 · 2023: $394 · 2024: $381 · 2025: $269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,044.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,044.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $447.91 | 2021-2025 | |
| Indivior INC. | $150.52 | 2021-2024 | Sublocade |
| Braeburn INC. | $118.83 | 2023-2025 | Brixadi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.39 | 2023-2024 | Xifaxan, Trulance |
| Insulet Corporation | $58.76 | 2024-2025 | Omnipod |
| Lilly USA, LLC | $46.10 | 2021-2023 | Jardiance, Emgality |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $45.63 | 2025 | Caplyta |
| Amgen INC. | $44.17 | 2024 | Otezla, Repatha |
| Alkermes, INC. | $42.13 | 2023-2024 | Vivitrol, Vivitrol |
| Vanda Pharmaceuticals INC. | $31.41 | 2025 | Fanapt |
| Xeris Pharmaceuticals, INC. | $21.75 | 2025 | Gvoke Hypopen |
| Pear Therapeutics (US), INC. | $21.23 | 2022 | |
| Pfizer INC. | $19.77 | 2025 | |
| Gilead Sciences, INC. | $17.59 | 2025 | |
| Novo Nordisk INC | $16.16 | 2024 | Ozempic, Rybelsus |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sequel Med Tech, LLC | $16.06 | 2025 | Twiist |
| Collegium Pharmaceutical, INC. | $14.56 | 2025 | Jornay Pm |
| Orexo US, INC. | $14.27 | 2023 | Zubsolv |
| Otsuka America Pharmaceutical, INC. | $12.63 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $12.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.